Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer

Fig. 1

a Survival fraction (SF) of A549 and H1299 cells exposed with 12C ion with and without olaparib (O). The survival fraction (SF) of olaparib treated cells at 0 Gy was corrected to 1 and all the olaparib treated cells were normalized accordingly. b represent the same data where survival fraction of untreated control was assumed as 1 and of all other treated cells (either 12C ion or olaparib or combined) normalized accordingly. c Time course cell proliferation in A549 cells after treatment with PARP-1 inhibitor DPQ (D) and olaparib (O) separately and in combination with 12C ion exposure (0–4 Gy). Each bar represents mean cell proliferation ± standard deviation obtained from three independent experiments. All the differences with respect to control are significant and p-values at each dose were p ≤ 0.001 in each cell-type

Back to article page
\